INT158374

Context Info Confidence 0.07 First Reported 2001 Last Reported 2011 Negated 0 Speculated 1 Reported most in Body Documents 13 Total Number 13 Disease Relevance 7.19 Pain Relevance 1.76

endoplasmic reticulum (Aadac)

Anatomy Link Frequency macrophages 1 Aadac (Mus musculus)

Pain Link Frequency Relevance Heat IPN 2 99.16 Inflammation 36 98.96 Pain 3 98.96 Hyperalgesia 1 98.88 anesthesia 3 98.68 endometriosis 2 97.32 Glutamate 1 96.80 depression 8 94.56 cINOD 12 87.36 Neuronal excitability 1 72.44

Disease Link Frequency Relevance Heat Cancer 81 100.00 Inflammatory Pain 2 99.16 Hyperalgesia 1 98.88 Breast Cancer 3 97.80 Muscular Atrophy 6 97.72 Acute Erythroblastic Leukemia 6 97.40 Endometriosis (extended) 2 97.32 Sprains And Strains 2 96.64 INFLAMMATION 41 95.28 Keloid Scars 4 94.60

Sentences Mentioned In

Key:

Protein

Mutation

Event

Anatomy

Negation

Speculation

Pain term

Disease term

Trichostatin A, a histone deacetylase inhibitor, reduces lesion growth and hyperalgesia in experimentally induced endometriosis in mice.

Negative_regulation (inhibitor) of deacetylase associated with endometriosis and hyperalgesia

1) Confidence 0.07 Published 2010 Journal Hum. Reprod. Section Title Doc Link 20118114 Disease Relevance 0.29 Pain Relevance 0.19

VPA is a histone deacetylase inhibitor, and it is possible that the differential teratogenesis in B6 and D2 is because of strain differences in histone acetylation.

Negative_regulation (inhibitor) of deacetylase associated with sprains and strains

2) Confidence 0.05 Published 2010 Journal Toxicol. Sci. Section Abstract Doc Link 20457659 Disease Relevance 0.39 Pain Relevance 0.14

Oral administration of sodium butyrate--a histone deacetylase inhibitor--resulted in the improvement of neurological dysfunction in the SBMA mouse model, although its therapeutic dose range is narrow.

Negative_regulation (inhibitor) of deacetylase associated with anesthesia and muscular atrophy

3) Confidence 0.02 Published 2009 Journal Brain Nerve Section Abstract Doc Link 19697878 Disease Relevance 1.06 Pain Relevance 0.10

Although it is very possible that our behavioral phenotypes are a result of the loss of the putative deacetylase domain, they could also be due to the low expression of the N-terminal domain.

Negative_regulation (loss) of deacetylase

4) Confidence 0.02 Published 2009 Journal PLoS ONE Section Body Doc Link PMC2720538 Disease Relevance 0.43 Pain Relevance 0.04

Epigenetic modulation of mGlu2 receptors by histone deacetylase inhibitors in the treatment of inflammatory pain.

Negative_regulation (inhibitors) of deacetylase associated with inflammation and ipn

5) Confidence 0.02 Published 2009 Journal Mol. Pharmacol. Section Title Doc Link 19255242 Disease Relevance 0.37 Pain Relevance 0.72

The butyrate moiety of arginine butyrate has been shown to inhibit histone deacetylase, resulting in hyperacetylation of histones H3 and H4.

Negative_regulation (inhibit) of deacetylase

6) Confidence 0.02 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2888587 Disease Relevance 0.10 Pain Relevance 0.03

It has been reported that the second generation of HPCs (suberoylanilide hydroxamic acid [SAHA]), structurally related to but 2000-fold more potent than HMBA, was an inhibitor of histone deacetylase activity and caused accumulation of hyperacetylated histone H4 in murine erythroleukemia.

Negative_regulation (inhibitor) of deacetylase associated with acute erythroblastic leukemia

7) Confidence 0.01 Published 2001 Journal Breast Cancer Res Section Body Doc Link PMC13923 Disease Relevance 0.25 Pain Relevance 0

We therefore suggest that the dose and time regimen for histone deacetylase inhibitors, such as SAHA, may have to consider the p53 status of breast cancers.

Negative_regulation (inhibitors) of deacetylase associated with breast cancer

8) Confidence 0.01 Published 2001 Journal Breast Cancer Res Section Body Doc Link PMC13923 Disease Relevance 0.42 Pain Relevance 0.32

SAHA was reported to be a histone deacetylase inhibitor and caused accumulation of hyperacetylated histone H4 in murine erythroleukemia [17].

Negative_regulation (inhibitor) of deacetylase associated with acute erythroblastic leukemia

9) Confidence 0.01 Published 2001 Journal Breast Cancer Res Section Body Doc Link PMC13923 Disease Relevance 0.70 Pain Relevance 0.03

Tumor-deacetylase activity decreased in eight patients in a statistically significant manner.

Negative_regulation (decreased) of Tumor-deacetylase associated with cancer

10) Confidence 0.01 Published 2011 Journal Journal of Biomedicine and Biotechnology Section Body Doc Link PMC3004414 Disease Relevance 1.28 Pain Relevance 0.05

Riggs and colleagues identified the HDACs inhibitor prototype sodium butyrate to be an effective inhibitor of deacetylase activity [32, 33].

Negative_regulation (inhibitor) of deacetylase

11) Confidence 0.01 Published 2011 Journal Journal of Biomedicine and Biotechnology Section Body Doc Link PMC3004414 Disease Relevance 0.61 Pain Relevance 0

The histone acetyltranferase CREB binding protein CBP is required for recognition memory (Barrett and Wood, 2008 for a review) and histone deacetylase inhibition enhances long-term recognition memory (Stefanko et al., 2009).

Negative_regulation (inhibition) of deacetylase

12) Confidence 0.01 Published 2010 Journal Frontiers in Behavioral Neuroscience Section Body Doc Link PMC2992451 Disease Relevance 0.57 Pain Relevance 0.03

To examine the effects of a histone deacetylase inhibitor, Trichostatin A (TSA), on the behavior of macrophages and subconjunctival fibroblasts in vitro and on ocular surface inflammation and scarring in vivo using an alkali burn wound healing model.

Spec (examine) Negative_regulation (inhibitor) of deacetylase in macrophages associated with inflammation, burns, wound healing and keloid scars

13) Confidence 0.00 Published 2010 Journal Molecular Vision Section Abstract Doc Link PMC3013068 Disease Relevance 0.65 Pain Relevance 0.13

General Comments

This test has worked.